Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Cell therapies constitute the largest number of agents in development in immuno-oncology (Nat. Rev. Drug Discov.18, 899–900; 2019). Here, we provide an update on the pipeline and clinical trials of cancer cell therapies. We also compare the current landscape (with a March 2020 data cut-off point) with our previous update from March 2019 (Nat. Rev. Drug Discov.18, 821–822; 2019).